Outlook Therapeutics has seen its analyst consensus price target increase from $1.90 to $2.80, driven by promising Phase III trial results for its eye disease drug ONS-5010 and strategic partnerships. The company is expected to beat upcoming quarterly earnings estimates, which could further boost investor confidence. Despite some cautious views, overall sentiment reflects growing optimism about the company's future performance in the biopharmaceutical sector.
Greg Abel, Warren Buffett's successor at Berkshire Hathaway, reduced the company's investment in Bank of America by $1.7 billion. At the same time, he increased the stake in Delta Air Lines by $1.6 billion. This shift in portfolio allocation highligh...
In June 2026, President Donald Trump executed more than 1,000 stock trades, including purchases in SpaceX shortly after its IPO and multiple transactions in tech and defense companies like Palantir. The largest trade was a sale of Vanguard ETF shares...
Bitcoin experienced a sharp flash crash, dropping over 6% after rising more than 25% this week and nearly touching $80,000. Despite this, BTC remains up over 21% for the week, indicating a healthy correction rather than a major crash. Strong inflows ...
XRP is experiencing its biggest weekly gain since late 2024, rising between 30% and 67% after the US Treasury announced it would double its long-term bond buyback program from $2 billion to $4 billion per operation starting September 9. This move has...
Eli Lilly reported a 47.67% revenue increase to $22.974 billion, driven by strong sales of Mounjaro at nearly $10 billion. Despite price pressures and higher tax rates, the company raised its full-year guidance, reflecting confidence in growth. Analy...
